Table 3.
P-gp inhibitors that have been evaluated in clinical trials.
| P-gp Inhibitor | Phase | Trial | Protocols Identification |
|---|---|---|---|
| Tariquidar (XR9576) | II | Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer | 03-C-0284, NCI-03-C-0284, NCT00072202, NCT00069160 |
| II | Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane and Tariquidar to Treat Adrenocortical Cancer | 040011, 04-C-0011, NCT00071058 | |
| I | Study of XR9576 and Vinorelbine in Patients with Advanced Cancer | NCI-00-C-0044 | |
| I | Trial of Tariquidar (XR9576) in Combination with Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients with Solid Tumors | NCT00011414 | |
| Zosuquidar (LY335979) | III | Daunorubicin and Cytarabine ± Zosuquidar in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | CDR0000257122 E3999, U10CA021115, ECOG-E3999, NCT00046930 |
| II | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55–75 with Newly Diagnosed Acute Myeloid Leukemia (AML) | KAN-979-01 NCT00129168 | |
| II | A Trial of Gemtuzumab Ozogamicin (GO) in Combination with Zosuquidar in Patients with CD33 Positive Acute Myeloid Leukemia | KAN-979-02 NCT00233909 | |
| Laniquidar (R101933) | II | R101933 Combined with Chemotherapy in Treating Patients with Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy | EORTC-10003-16004 EORTC-16004, ECSG-EORTC-16004, IDBBC-10003, NCT00028873 |
| Elacridar (GF120918) | I | A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) in Combination with 2.0 mg Oral Topotecan in Cancer Patients | BCR10001 |
| Mitotane (NSC-38721) | III | Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) | CO-ACT-001 NCT00094497 |
| II | Phase II Study of Continuous-Infusion DOX/VCR/VP-16 with Daily Oral Mitotane for Renal Cell Cancer | NCI-94-C-0156 | |
| II | Phase II Mitotane plus Cortisone Acetate/Fludrocortisone and ADR for Residual, Recurrent or Metastatic Adrenal Cortical Carcinoma | EST-1879 | |
| II | Phase II Study of Continuous-Infusion DOX/VCR/VP-16 with Daily Oral Mitotane Before and After Surgery in Patients with Adrenocortical Carcinoma | NCI-93-C-0200D NCI-93-C-0200B | |
| Annamycin | II | Chemotherapy in Treating Patients with Breast Cancer | CDR0000068486 NYU-9851, NCI-G01-1914, NCT00012129 |
FIRM-ACT: First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment; DOX: Doxorubicin; VCR: Vincristine; VP-16: Etoposide; ADR: Adriamycin.